Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies [version 1; peer review: 3 approved]
Dermatomyositis (DM) is an inflammatory myopathy with characteristic skin manifestations, the pathologies of which are considered autoimmune diseases. DM is a heterogeneous disorder with various phenotypes, including myositis, dermatitis, and interstitial lung disease (ILD). Recently identified myos...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2019-11-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/8-1951/v1 |
| _version_ | 1818146440726183936 |
|---|---|
| author | Naoko Okiyama Manabu Fujimoto |
| author_facet | Naoko Okiyama Manabu Fujimoto |
| author_sort | Naoko Okiyama |
| collection | DOAJ |
| description | Dermatomyositis (DM) is an inflammatory myopathy with characteristic skin manifestations, the pathologies of which are considered autoimmune diseases. DM is a heterogeneous disorder with various phenotypes, including myositis, dermatitis, and interstitial lung disease (ILD). Recently identified myositis-specific autoantibodies have been associated with distinct clinical features. For example, anti-melanoma differentiation-associated protein 5 antibodies have a high specificity for clinically amyopathic DM presenting rapidly progressive ILD. Furthermore, anti-transcriptional intermediary factor 1γ antibodies found in patients with juvenile and adult DM are closely correlated with malignancies, especially in elderly patients. Finally, patients with anti-aminoacyl-transfer RNA synthetase antibodies share characteristic clinical symptoms, including myositis, ILD, arthritis/arthralgia, Raynaud’s phenomenon, and fever; thus, the term “anti-synthetase syndrome” is also used. With a focus on the characteristic cutaneous manifestations in each subgroup classified according to myositis-specific autoantibodies, we introduce the findings of previous reports, including our recent analysis indicating that skin eruptions can be histopathologically classified into myositis-specific autoantibody-associated subgroups and used to determine the systemic pathologies of the different types of antibody-associated DM. |
| first_indexed | 2024-12-11T12:19:23Z |
| format | Article |
| id | doaj.art-8c941a2ca1794f3cae15ae21e1721519 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-11T12:19:23Z |
| publishDate | 2019-11-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-8c941a2ca1794f3cae15ae21e17215192022-12-22T01:07:34ZengF1000 Research LtdF1000Research2046-14022019-11-01810.12688/f1000research.20646.122708Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies [version 1; peer review: 3 approved]Naoko Okiyama0Manabu Fujimoto1Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305-8575, JapanDepartment of Dermatology, Integrated Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, JapanDermatomyositis (DM) is an inflammatory myopathy with characteristic skin manifestations, the pathologies of which are considered autoimmune diseases. DM is a heterogeneous disorder with various phenotypes, including myositis, dermatitis, and interstitial lung disease (ILD). Recently identified myositis-specific autoantibodies have been associated with distinct clinical features. For example, anti-melanoma differentiation-associated protein 5 antibodies have a high specificity for clinically amyopathic DM presenting rapidly progressive ILD. Furthermore, anti-transcriptional intermediary factor 1γ antibodies found in patients with juvenile and adult DM are closely correlated with malignancies, especially in elderly patients. Finally, patients with anti-aminoacyl-transfer RNA synthetase antibodies share characteristic clinical symptoms, including myositis, ILD, arthritis/arthralgia, Raynaud’s phenomenon, and fever; thus, the term “anti-synthetase syndrome” is also used. With a focus on the characteristic cutaneous manifestations in each subgroup classified according to myositis-specific autoantibodies, we introduce the findings of previous reports, including our recent analysis indicating that skin eruptions can be histopathologically classified into myositis-specific autoantibody-associated subgroups and used to determine the systemic pathologies of the different types of antibody-associated DM.https://f1000research.com/articles/8-1951/v1 |
| spellingShingle | Naoko Okiyama Manabu Fujimoto Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies [version 1; peer review: 3 approved] F1000Research |
| title | Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies [version 1; peer review: 3 approved] |
| title_full | Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies [version 1; peer review: 3 approved] |
| title_fullStr | Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies [version 1; peer review: 3 approved] |
| title_full_unstemmed | Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies [version 1; peer review: 3 approved] |
| title_short | Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies [version 1; peer review: 3 approved] |
| title_sort | cutaneous manifestations of dermatomyositis characterized by myositis specific autoantibodies version 1 peer review 3 approved |
| url | https://f1000research.com/articles/8-1951/v1 |
| work_keys_str_mv | AT naokookiyama cutaneousmanifestationsofdermatomyositischaracterizedbymyositisspecificautoantibodiesversion1peerreview3approved AT manabufujimoto cutaneousmanifestationsofdermatomyositischaracterizedbymyositisspecificautoantibodiesversion1peerreview3approved |